Objective: To report the time of delay in thrombolysis of massive and submassive pulmonary embolism (PE). Methods: We enrolled 83 consecutive patients with massive and submassive PE from 8 hospitals between June 2006 and March 2009. We recorded the delay between symptom onset and thrombolysis. The clinical findings related to early thrombolysis (delay 2 days) were analyzed. Results: Median of the delay in thrombolysis was 8 days with 82% over 2 days, 53% over 7 days, and 6% over 25 days. Compared to the late thrombolysis (delay >2 days), patients with early thrombolysis more frequently had murmurs at the tricuspid area (26.7% vs 6.1%, P ¼ .053), less frequently had cough (20% vs 59.7%, P ¼ .005) and increased P2 (pulmonic component of second heart sound; 33.3% vs 61.2%, P ¼ .049), and more patients were thrombolysed in off-hours (86.7% vs 57.4%, P ¼ .034). Conclusion: The time of delay in thrombolysis is too long and the symptoms and signs between early and late thrombolysis groups may differ.
Introduction
Pulmonary embolism (PE) is a common cardiovascular illness. 1 Characteristics of massive PE include cardiogenic shock and/or persistent arterial hypotension. Patients with submassive PE are defined as those with objectively confirmed PE accompanied with right ventricular dysfunction (RVD) identified by echocardiography or computed tomography (CT). 2, 3 Thrombolysis is an established treatment for massive PE, 4 and thrombolytic therapy may be also considered in selected patients with submassive PE. 1 Evidence that thrombolysis can prevent clinical deterioration requiring the escalation of treatment in submassive PE during the hospital stay exists. 2 The mortality of massive and submassive PE is higher than that of nonmassive PE (PE that does not meet the diagnostic criteria for being massive/submassive). 1 In fatal cases, it has long been recognized that two thirds of the patients will die within 1 hour of presentation. 5, 6 Therefore, the thrombolytic treatment should be commenced as soon as possible after massive and submassive PE are diagnosed. 7 Earlier diagnosis and treatment of PE may reduce the morbidity and mortality associated with venous thromboembolism (VTE). 5 The greatest benefit is observed when thrombolytic treatment is initiated within 2 days (48 hours) of symptom onset. 1, 8 However, data regarding delays in thrombolysis of massive and submassive PE are sparse. Therefore, we undertook a prospective study at 8 medical centers in China to investigate the time of delay in thrombolysis of massive and submassive PE and its correlation with patients' clinical findings. We also reported the differences in thrombolytic treatments conducted by the medical center with adequate experience and the other centers in off-hours.
Materials and Methods
The study was performed in 8 general hospitals (see ''Appendix'') from 7 provinces of mainland China from June 1, 2006 , to March 31, 2009 . Each hospital has more than 1000 beds. Patients aged 18 to 75 years, with acute pulmonary thromboembolism, were assessed for eligibility. All diagnoses were confirmed either by the presence of an intraluminal filling defect on spiral computed tomographic pulmonary angiography (CTPA) or by a high-probability ventilation/perfusion (V/Q) scan. To be included in the study, patients with acute PE had to fulfill both of the following criteria. First, patients needed to experience either massive or submassive PE. Massive PE is defined as presented with hemodynamic instability (systolic blood pressure <90 mm Hg or a fall in systolic blood pressure of <40 mm Hg from baseline for at least 15 minutes or a pulmonary capillary occlusion pressure >15 mm Hg and a cardiac index <2.2 L/min per square meter). 1, 9 Submassive PE is defined as associated with RVD. The RVD diagnosis is supported by the radiologic findings on echocardiography including right ventricular dilation (defined as ratio of diastolic diameters of right/left ventricular [RV/LV] >1, or ratio of right/left ventricular end-diastolic diameter in the parasternal long-axis view [RVED/LVED] >0.5, or RVED >25 mm), right ventricular hypokinesis (defined as right ventricular free wall motion <5 mm), or tricuspid regurgitant pressure gradient (TRPG) >30 mm Hg in the absence of left ventricular or mitral valve disease or right ventricular free wall thickness >7 mm. [1] [2] [3] [10] [11] [12] [13] The diagnosis of RVD is also supported by RV/LV >0.9 on CT imaging. 14, 15 Second, patients were required to have presented with symptoms consistent with cardiovascular deterioration (particularly dyspnea, syncope, arterial hypotension, shock, worsening respiratory failure, or persistent or worsening RVD) less than 14 days before diagnosis. We excluded the patients who had contraindications to fibrinolytic therapy. 2 Once diagnosed, all the enrolled patients received thrombolytic treatment in our study. The protocol was approved by the local ethics committee in each institution, and written informed consent was obtained from each patient.
Demographics, risk factors for VTE, symptoms, and physical signs were recorded in a standardized questionnaire just before thrombolysis by investigators. Any symptom reported by that patient and potentially attributable to PE (including dyspnea, chest pain, cough, hemoptysis, palpitation, and syncope) was recorded on a standardized history form regardless of whether they were relieved by therapy administered for PE. The date of the first symptom onset and starting time (date, hour, minute) of thrombolytic treatment was recorded. Then, the total time of delay in thrombolysis (days) was calculated. The ''early thrombolysis group'' consisted of patients receiving thrombolysis within 2 days of symptom onset, while the ''late thrombolysis group'' included those patients with a delay to thrombolysis >2 days from the onset of symptoms. The starting time of thrombolytic treatment was dichotomized into regular hours (weekdays 8 AM-5 PM) and off-hours (weekdays 5 PM-8 AM, weekends, and holidays). The outcomes (death and recurrent VTE) were followed up in 14 days after thrombolysis with recurrent VTE confirmed by CTPA, V/Q scan, or ultrasound.
Statistical Analysis
A software package (Statistical Package for the Social Sciences [SPSS] version 11.5 for Windows; SPSS, Inc) was used to plot histogram of delay time, and the data were then tested using Kolmogorov-Smirnov test for normality. If delay time distributions were significantly different from normal distributions, they were described by median and quartile. Comparisons of continuous data between groups were performed using independent-samples t test, and the values were reported as mean + SD. Categorial data were compared using chisquare test and Fisher test (2 Â 2 table). The correlations between early thrombolysis and clinical findings, V/Q scan, and thrombolysis in off-hours were first evaluated by univariate logistic regression analysis and then the parameters P < .20 were included in multivariate logistic regression analysis. Findings are given as odds ratio (OR; 95% confidence interval [CI]). A P value of less than .05 was considered statistically significant. All reported P values are 2-sided.
Results
Seven hundred seventy-five consecutive patients with objectively confirmed acute symptomatic PE found on CTPA or V/Q scan were assessed for eligibility from June 1, 2006, to March 31, 2009. If clinical signs of RVD (such as increased P2 [pulmonic component of second heart sound], murmurs at the tricuspid area, jugular vein distension, hepatomegaly, and peripheral edema) were present on physical examination, or right ventricular dilatation was seen on CTPA, then echocardiography was performed. A total of 688 patients were excluded from the study because they presented with nonmassive PE. Another 4 patients were excluded because of data incompletion, leaving a study population of 83 patients. The average age of the patients was 55.7 + 13.7 years, and 37 (45%) were male. There were 11 patients with massive PE enrolled. The risk factors for VTE and clinical characteristics are described in Table 1 . All the enrolled patients received CTPA to diagnose, while V/Q scan was conducted in 20 patients initially. In 14 days follow-up, mortality rate was low, with 2 (2.4%) patients dead (one due to fatal recurrent PE and the other due to active cancer). Figure 1 identifies the total time of delay in thrombolysis, and the distribution was significantly different from normal distribution (P ¼ .001). The median was 8 days and the quartile interval was 9 days. Only 15 of 83 patients (18%) received early thrombolysis, 68 patients (82%) had >2 days delay between symptom onset and thrombolysis, 44 patients (53%) had >7 days delay, 17 patients (21%) had >14 days delay, and 5 patients (6%) had >25 days delay. Those patients who are younger than 65 years received thrombolysis a little earlier than those aged older than 65 years (10.0 + 10.2 vs 11.3 + 12.6 days, P ¼ .608). Delay for patients with cardiopulmonary diseases was 9.5 + 10.8 days, while for other patients with no comorbidity 11.1 + 11.0 days (P ¼ .522). No significant difference in the time of delay was observed between patients with massive and submassive PE (9.3 + 11.4 vs 10.5 + 10.8 days, P ¼ .722).
Delay in Thrombolysis

Differences Between Early and Late Thrombolysis
Compared to patients with late thrombolysis, patients with early thrombolysis more frequently had murmurs at the tricuspid area (26.7% vs 6.1%, P ¼ .053) and less frequently had cough (20% vs 59.7%, P ¼ .005) and increased P2 (33.3% vs 61.2%, P ¼ .049). Interestingly, more patients were thrombolysed in off-hours in the early thrombolysis group (86.7% vs 57.4%, P ¼ .034). Both deaths occurred in the late thrombolysis group (Table 1) . One patient with active cancer died 5 days after thrombolysis (with 3 days' delay) due to recurrent PE, and the other died 8 days after thrombolysis (with 13 days' delay) due to active cancer.
Correlation Between Early Thrombolysis and Clinical Parameters
Univariate logistic regression analysis identified that sex, recent surgery, cough, hypotension, crackles, murmurs at the tricuspid area, increased P2, V/Q scan, and thrombolysis in off-hours may have a potential association with early thrombolysis (Table 1) . Multivariate analysis confirmed a statistically significant association between baseline characteristics of cough, crackles, murmurs at the tricuspid area, an increased P2, and early thrombolysis ( Table 2) .
Thrombolysis in Off-Hours at Different Hospitals
Fifty-two (63%) of all the 83 patients received thrombolysis in off-hours. Beijing Chao-Yang hospital, which has an established rapid reaction team and emergency radiogenic testing system for diagnosis and treatment of PE, enrolled most cases (n ¼ 29). The percentage of off-hours thrombolysis at Chao-Yang hospital was 76% while that at the other 7 centers was 56%, P ¼ .068.
Discussion
Because an estimated 11% of patients with acute PE die within 1 hour, rapid evaluation and early diagnosis is essential. Integration of historical information and examination findings with laboratory data and a structured approach to diagnosis and resuscitation facilitate optimal therapeutics in this ''golden hour.'' 6 Our previous animal research revealed that thrombolysis at 0.5 hours after the establishment of canine PE model can make dramatic improvement on hemodynamics and pulmonary angiography. 16 Although patients benefit greatly from early thrombolysis (treatment initiated within 2 days of symptom onset), 1,8 when this is not possible, value in the delayed application of thrombolysis still exists. Daniels et al reviewed 5 PE thrombolysis trials and found that thrombolysis is still useful in patients who have had symptoms for 6 to 14 days. 7 Chao et al also reported that delayed thrombolytic therapy can still be beneficial in selected cases, even if more than 1 month after symptom onset. 17 However, for each additional day of symptoms before PE thrombolysis, there was a decrement of 0.8% of lung tissue reperfusion on lung scanning. Similarly, on angiography, less clot lysis was observed in the group of patients with symptoms for 6 to 14 days compared with 1 day. 7 A multicenter thrombolytic trial launched in China (n ¼ 95) indicated that the best efficacy was demonstrated in patients within 1 week after symptom onset, but thrombolysis was still effective in patients with symptoms for more than 14 days. 18 The distribution of delay in thrombolysis had 2 peaks in our research (Figure 1) , one on the first day and the other on the twelfth day. Twelve patients (14%) received thrombolysis 1 day after onset of PE symptoms. Most of them had syncope, severe shortness of breath, or hypotension, which made them seek medical attention immediately. However, the majority of the enrolled patients received thrombolytic treatment during days 2 to 15 in our study. The patients' negligence of some mild symptoms might be a cause of the delay. Two recent studies from North America (n ¼ 344) 19 and Spain (n ¼ 397) 20 documented the time of delay in diagnosis (including nonmassive PE). The distribution in those two studies was a descending curve, and the peak appeared on the first day. The 2 studies showed that 17% to 18% of the patients with acute PE were diagnosed more than a week after symptom onset, and 5% to 6% patients had the delay of more than 25 days. Bulbul et al 21 reported that 31.6% of the patients presented within the first 24 hours and an additional 38.0% presented within the first week. Although the nonmassive PE was included in their studies, the status of delay seemed still better than that of our study.
Comparing the delay to diagnosis times we observed with the aforementioned studies, we perceive opportunities for improving the public education and clinical acumen of health care providers to promote the early diagnosis and therapy for PE in China. A recent systematic review and meta-analysis showed that individual clinical features only slightly raise or lower the probability of PE, and they have limited diagnostic value with none being useful for ruling in or out PE without further diagnostic testing. 22 However, some symptoms and physical findings seemed to have some relationship to early thrombolysis in our research. Crackles and murmurs at the tricuspid area may be potential ''early'' clues; in contrast, cough and increased P2 may be potential ''late'' clues. The study by Bulbul et al 21 also revealed that patients with a high body temperature (P ¼ .024) or hypotension (P ¼ .040) tend to present earlier, while the presence of a cough (P ¼ .019) was related to delayed presentation. Thus, careful collection of clinical features may help the doctors to evaluate the stages of PE. However, the reason why different stages presented different clinical features in our study is yet to be investigated. Further basic and clinical studies are needed to confirm it.
Furthermore, off-hours may be another factor to which we need to pay attention. Previous studies on acute myocardial infarction (AMI) have revealed that the delay time from symptom onset to thrombolysis can influence the outcomes of AMI, 23, 24 and off-hours may be an important factor to prolong the reperfusion time. 25, 26 More than half of all the 83 patients received thrombolysis in off-hours in our research, and the percentage of off-hours thrombolysis at Chao-Yang hospital was a little more than that of the other 7 centers (P ¼ .068). However, due to the concern of major bleeding, some doctors intended to conduct thrombolytic treatment in regular hours, when the support from the multidisciplinary team is easier to reach. Widely used emergency CTPA and echocardiography and more experienced senior and junior doctors for PE may facilitate the off-hours thrombolysis and shorten the delay in diagnosis and treatment. The admission process and transportation may also prolong the time of delay in thrombolysis for PE. Thus, simplifying the whole process of diagnosis and treatment is necessary.
Study Limitation
There are a few limitations in our study. First, the reasons leading to delay in individual patients are not indicated. We considered that the patients' negligence of the symptoms might be a major cause of the delay. Second, detailed delay time of symptoms onset to diagnosis and diagnosis to thrombolysis is not mentioned. Due to the condition limitations, we did not monitor the diagnostic time to analyze the delay in diagnosis and treatment separately for all the patients from all the hospitals. However, we have selected a representative hospital with full data to make further analysis, intending to report the results shortly. Finally, this article does not demonstrate that the delay in thrombolysis leads to a higher mortality or higher recurrence rate, but we do not think the time delay is unimportant. A larger sample size and longer follow-up may be helpful to reveal the relationship between time delay and prognosis.
Conclusion
The time of delay between symptom onset and thrombolysis is too long for the patients with massive and submassive PE in our study. The symptoms and clinical signs between early and late thrombolysis groups may differ. Crackles and murmurs at the tricuspid area may be potential ''early'' clues; in contrast, cough and an increased P2 may be potential ''late'' clues. Therefore, an elevated level of clinical suspicion for PE coupled with a careful physician examination may reduce the delay time for the diagnosis of PE. Most of the patients received thrombolysis in off-hours, and so the establishment of a high-quality PE rapid reaction team might be helpful.
